|
Post by harryx1 on Jun 11, 2015 13:57:50 GMT -5
|
|
|
Post by mnholdem on Jun 11, 2015 14:00:38 GMT -5
I sure admire the way you think ahead, harry!
|
|
|
Post by jpg on Jun 11, 2015 15:00:58 GMT -5
Wow... Actually double wow!
|
|
|
Post by oscarlonzo on Jun 11, 2015 18:56:32 GMT -5
According to the CDC, there are 21 million people with diabetes in the United States. Of that, 2-3 million take no medication. 11-12 million take only pills. 2-3 million take pills plus insulin and 2-3 million take only insulin. So what you really need to know is how many of the 4-6 million taking insulin, how many read any of those magazines. Ultimately, you won't really know the ad impact until several months later. Something further to consider is the nature of the ads. What will they say? If they turn out like the "afrezza.com" website, then SNY could end up driving away consumers because that is probably the most dismal website for a drug I've ever seen.
|
|
|
Post by notamnkdmillionaire on Jun 11, 2015 19:48:24 GMT -5
It is too bad that Google's glucose reading contact lens isn't commercialized yet. All Sanofi would have to do is run a banner add for Afrezza and it would flash across the eyes of all those who wear the lens.
|
|
|
Post by mannmade on Jun 11, 2015 21:56:24 GMT -5
According to the CDC, there are 21 million people with diabetes in the United States. Of that, 2-3 million take no medication. 11-12 million take only pills. 2-3 million take pills plus insulin and 2-3 million take only insulin. So what you really need to know is how many of the 4-6 million taking insulin, how many read any of those magazines. Ultimately, you won't really know the ad impact until several months later. Something further to consider is the nature of the ads. What will they say? If they turn out like the "afrezza.com" website, then SNY could end up driving away consumers because that is probably the most dismal website for a drug I've ever seen. My understanding that as of 2014 there were 29m diabetics in the United States and another 60m pre-diabetic. Afrezza was originally planned for launch to be taken by the insulin naive T2's. Also part of the strategy for Afrezza as I understand it is to make prandial insulin one for the first therapies for T2's (eliminating the "Lost Decade") before basil and instead of many of the orals which have some nasty side effects. Now I recognize this is part of the paradigm shift and will take a bit of time but it also changes your estimated numbers for the US. As for the website it was likely done by an internal digital staff (although I do not know) and has many FDA restrictions. Could it be more appealing, probably, but if the drug works then all people really need is information. And regarding the magazine ads, there are many ways the creative can be handled. My suggestion would be to run two ads side by side, one for Afrezza, extolling the benefits (as much as you can say within FDA review) and the second as a testimonial from a real user who can speak to his interpretation (personal experiences from using Afrezza) of the points made in the first ad. For the creative on the first some topics/bullet points that they could incorporate into their messaging is as follows: 1.) No more needles at mealtime and all the benefits of this 2.) Fast in/Fast out, 3.) Real time management of your diabetes Then have the second adjacent ad with the testimonial can give specific personal responses to the above topics, such as: 1.) I don't have to use needles at mealtime, much more convenient when I am at a restaurant, on an airplane or a date... And no more scarring 2.) Afrezza is so fast in and out that I don't have to take my prandial insulin 30 mins before I eat, I can take it with my meal and I have no severe lows with Afrezza because there is no stacking of insulin with the fast out profile 3.) With my CGM I now have real time management of my diabetes which means I can stay in zone between 90 and 140 BG 80% of the day which has helped lower my HBAic to 5.9 which is normal. I am now living with a non diabetic level and feel much better. Just my 2 cents...
|
|
|
Post by harryx1 on Jun 26, 2015 7:47:22 GMT -5
|
|
|
Post by dudley on Jun 26, 2015 10:59:11 GMT -5
Holy Cow, Harry - you are truly a magician! This is great stuff (not that we didn't all know it already but it is really refreshing to see it coming out now in so many places). Look at the insulin-c hart file and Afrezza just LEAPS out at you with the peak and duration time frames compared to the RAA's. It's almost laughable to see. Thanks again!
|
|
|
Post by babaoriley on Jun 26, 2015 11:34:34 GMT -5
Okay, Harry, enough with the bread crumbs. Stop fooling around and just flip all the cards and get down to it - tell us the MNKD stock price as of December 31, 2016 and December 31, 2017! That's what we really need to know, and I have a feeling you know it!
|
|
|
Post by harryx1 on Jun 26, 2015 12:33:56 GMT -5
Okay, Harry, enough with the bread crumbs. Stop fooling around and just flip all the cards and get down to it - tell us the MNKD stock price as of December 31, 2016 and December 31, 2017! That's what we really need to know, and I have a feeling you know it! LOL, Baba!!! That would require a time machine which the only one that I know that exist is the Wayback Machine and unfortunately it only goes back in time not forward.
|
|
|
Post by harryx1 on Jun 30, 2015 18:38:31 GMT -5
Here it is folks!!!!!!.... The First Ad!
|
|
|
Post by liane on Jun 30, 2015 18:41:44 GMT -5
Way to go harry!
|
|
|
Post by _neil on Jun 30, 2015 19:45:30 GMT -5
Sweet find. What do you guys think of this slogan for Afrezza? " Breathe. Easy. " Sorry if someone else already thought of this.
|
|
|
Post by dreamboatcruise on Jun 30, 2015 19:57:15 GMT -5
Anyone know what the ad rates are for that magazine? Perhaps our all knowing, yet non time traveling, yeti?
|
|
|
Post by peppy on Jun 30, 2015 20:10:06 GMT -5
Decisions are made for many reasons. The Afrezza user in the "advertisement" looks a bit of a vagabond. Consider a clean shaven individual with hair. Just sayin.
|
|